San Diego-based mostly Viking Therapeutics marked by itself as a serious competitor during the weight loss drug marketplace in February right after revealing promising data from the mid-stage trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection and in March th